Affiliation: GSF-National Research Center for Environment and Health
- Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen deliveryGerd Sutter
GSF Institut f Molekulare Virologie, Trogerstr 4b, 81675 Munchen, Germany
Curr Drug Targets Infect Disord 3:263-71. 2003..In this article we briefly review history of MVA and state-of-the art technologies with regard to generation of recombinant MVA vaccines, and describe the progress to develop MVA vector vaccines against important infectious diseases...
- Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivoI Drexler
GSF Institute for Molecular Virology, Munich, Germany
Cancer Res 59:4955-63. 1999..The results are an essential basis for MVA-based vaccination trials in cancer patients...
- Live viral vectors: vaccinia virusCaroline Staib
GSF Institute of Molecular Virology and Institute of Virology, Technical University Munich, Munich, Germany
Methods Mol Med 87:51-68. 2003
- Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapyKlaus Uberla
Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany
J Med Primatol 36:2-9. 2007..Therefore, we studied the concept of therapeutic immunization in 18 rhesus monkeys infected with a highly pathogenic simian immunodeficiency virus (SIV) swarm...
- Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individualsAntonio Cosma
Institute of Molecular Virology, GSF-National Research Centre for Environment and Health, 85764 Neuherberg, Germany
Vaccine 22:21-9. 2003..Furthermore, the new putative CD4 epitopes described here hold promise as important tools for epitope-based vaccination...
- Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?Ingo Drexler
Institute for Molecular Virology, Munchen, Germany
Curr Opin Biotechnol 15:506-12. 2004..Thus, vector development to challenge dilemmas in vaccinology or immunization against poxvirus bio-threat seems possible, yet the right choice should be made for a most beneficial use...
- Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virusAntonio Cosma
Institute of Molecular Virology, GSF National Research Centre for Environment and Health, Neuherberg, Germany
Clin Diagn Lab Immunol 11:406-10. 2004..Most importantly, application of the highly attenuated MVA eliminates the safety concern in using the replication-competent vaccinia virus in the standard clinical laboratory...
- A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)Ralf G Meyer
III. Medizinische Klinik, Johannes Gutenberg-Universitaet, Langenbeckstrasse 1, 55116 Mainz, Germany
Cancer Immunol Immunother 54:453-67. 2005..We presume that modification of the antigen and/or prime-boost vaccination applying different approaches to antigen delivery may be required to induce an effective tyrosinase-specific immune response...
- Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsGerald V Quinnan
Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA
J Virol 79:3358-69. 2005..Induction of cross-reactive, primary HIV-1-neutralizing antibodies is feasible and, when potent, may result in complete protection against infection with a heterologous challenge virus strain...
- Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus AnkaraCaroline Staib
GSF Institute of Molecular Virology and Institute of Virology, Technical University of Munich, Trogerstrasse 4b, , Germany
J Gen Virol 86:1997-2006. 2005..These data suggest that deletion of the viral IL1betaR gene may be considered a relevant approach to amplify the virus-specific CD8+ memory T-cell response and duration of protective immunity obtained after MVA vaccination...
- Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induce a type I IFN receptor-dependent switch to neutralizing IgG antibodiesPatricia Bach
Division of Immunology, Paul Ehrlich Institut, Langen, Germany
J Immunol 178:5839-47. 2007..Interestingly, in the context of VLP-VSV as well as VSV immunization, IFNAR triggering of B lymphocytes did not play a critical role...
- Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression followHelen Horton
Wisconsin Regional Primate Research Center, University of Wisconsin, Madison, Wisconsin 53715, USA
J Virol 76:7187-202. 2002..01). However, despite the induction of virus-specific cellular immune responses and reduced peak viral loads, most animals still suffered from gradual CD4 depletion and progressed to disease...
- Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaquesCharlotta Nilsson
Swedish Institute for Infectious Disease Control and Microbiology and Tumor Biology Center, Karolinska Institute, SE-171 82 Solna, Sweden
J Gen Virol 83:807-18. 2002..Furthermore, immunization with MVA-SIVsm, as well as wild-type MVA alone, seemed to delay disease progression after mucosal SIV infection in a proportion of the monkeys...
- Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditionsJutta Veits
Institute of Molecular Biology, Friedrich Loeffler Institut, Federal Research Institute for Animal Health, Südufer 10, Greifswald Insel Riems, Germany
Vaccine 26:1688-96. 2008....
- Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replicationTodd M Allen
Wisconsin Regional Primate Research Center, University of Wisconsin, Madison, Wisconsin 53715, USA
J Virol 76:4108-12. 2002..Despite the induction of Tat-specific CTL, there was no significant reduction in either peak or viral set point compared to that of controls...
- Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08Bernard Verrier
UMR 2142 CNRS bioMérieux, ENSL, 69365 Lyon, France
DNA Cell Biol 21:653-8. 2002....
- Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAARTAntonio Cosma
Institute of Molecular Virology, GSF National Research Centre of Environment and Health, Munich, Germany
AIDS Res Hum Retroviruses 23:782-93. 2007..The observed immune responses suggest that the highly attenuated MVA could be used as a substitute vaccine against smallpox in chronically HIV-1-infected individuals undergoing HAART...
- Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challengeAdriaan F G Antonis
Animal Sciences Group, Division of Infectious Diseases, P O Box 65, NL 8200AB Lelystad, The Netherlands
Vaccine 25:4818-27. 2007..Immunized animals showed reduced pulmonary virus loads, and no eosinophilic infiltration or enhanced respiratory distress. In conclusion, candidate rMVA/bRSV vaccines induced protective and safe immune responses in calves...
- Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus AnkaraHolger Ludwig
Department of Virology, Paul-Ehrlich-Institut, Langen, Germany
J Gen Virol 87:1145-55. 2006..These data imply that an essential function of vaccinia virus E3L is to secure translation of intermediate RNA and, thereby, expression of other viral genes...
- The highly conserved orthopoxvirus 68k ankyrin-like protein is part of a cellular SCF ubiquitin ligase complexKarin M Sperling
Paul Ehrlich Institut, Department of Virology, Paul Ehrlich Strasse 51 59, 63225 Langen, Germany
Virology 374:234-9. 2008..This interaction was F-box domain dependent and could also be observed in infected cells, indicating that SCF complex formation might be important for the viral life cycle...
- Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus AnkaraCaroline Staib
GSF - Institute of Molecular Virology and Institute of Virology, Technical University of Munich, , Germany
J Gen Virol 87:2917-21. 2006..These data suggest that, in addition to conventional vaccination, MVA may serve for potent emergency prophylaxis against orthopoxvirus infection...
- Vaccinia virus replication is not affected by APOBEC3 family membersMelanie Kremer
Paul Ehrlich Institut, Paul Ehrlich Str, 51 59, 63225 Langen, Germany
Virol J 3:86. 2006..In addition, poxviruses replicate exclusively in the cytoplasm where APOBEC3G is located. It was therefore tempting to analyze whether vaccinia virus replication is affected by APOBEC3G...
- T cell responses to respiratory syncytial virus fusion and attachment proteins in human peripheral blood mononuclear cellsLeon de Waal
Department of Virology, Erasmus MC, Rotterdam, The Netherlands
Viral Immunol 19:669-78. 2006..The rMVA-based in vitro stimulation protocol will be useful to define protein-specific T cell responses in different viral systems...
- Vaccinia virus double-stranded RNA-binding protein E3 does not interfere with siRNA-mediated gene silencing in mammalian cellsMarkus Lantermann
Paul Ehrlich Institut, Paul Ehrlich Str 51 59, 63225 Langen, Germany
Virus Res 126:1-8. 2007....
- Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1Joost H C M Kreijtz
Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands
J Infect Dis 195:1598-606. 2007..Our data suggest that recombinant MVA expressing the HA of influenza virus A/Vietnam/1194/04 is a promising alternative vaccine candidate that could be used for the induction of protective immunity against various H5N1 influenza strains...
- Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicityChristine S Rollier
Department of Virology, Biomedical Primate Research Center, GH Rijswijk, The Netherlands
Hepatology 45:602-13. 2007..CONCLUSION: Despite early control of virus load, a virus-associated tolerogenic-like state can develop in certain individuals independent of vaccination history...
- Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responsesZoe Waibler
Division of Immunology, Paul Ehrlich Institut, D 63225, Langen, Germany
J Virol 81:12102-10. 2007..These data provide the basis to further improve MVA as a vaccine vector...
- Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccinesGeorg Gasteiger
GSF Institute for Molecular Virology, Schneckenburgerstrasse 8, D 81675 Munich, Germany
J Virol 81:11925-36. 2007..Our data are essential for improved MVA vaccine design, as they demonstrate the need for optimal adjustment of the target antigen properties to the intrinsic requirements of the delivering vector system...
- Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse modelSusanne El Gogo
Institute of Virology, Technical University Munchen, Germany
Vaccine 25:3934-45. 2007..These data strongly suggest the usefulness of the MHV-68 challenge model for further evaluation of recombinant vaccines against persisting virus infections...
- Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicityWolfgang Kastenmuller
GSF Institut für Molekulare Virologie, Klinikum rechts der Isar, Technische Universität 81675 München, Germany
Virology 350:276-88. 2006..These findings allow to better define the requirements for MVA-mediated antigen delivery to DC and help to derive optimized vectors for this advanced therapy option...
- A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNAKen J Ishii
Exploratory Research for Advanced Technology, Japan Science and Technology Agency, Research Institute for Microbial Diseases, Osaka University, Osaka 565 0871, Japan
Nat Immunol 7:40-8. 2006..These results suggest that both TBK1 and IKKi are required for innate immune activation by B-DNA, which might be important in antiviral innate immunity and other DNA-associated immune disorders...
- The poxviral scrapin MV-LAP requires a myxoma viral infection context to efficiently downregulate MHC-I moleculesNicolas Collin
, INRA ENVT, , 23 Chemin des Capelles, BP87614, 31076 Toulouse cedex 03, France
Virology 343:171-8. 2005..Our data suggest that the functionality of viral LAP factors, inherited by herpes- and poxviruses from mammalian cells, is more complex than anticipated...
- Comparison of the efficacy of early versus late viral proteins in vaccination against SIVKoert J Stittelaar
Department of Virology, Erasmus Medical Centre Rotterdam, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
Vaccine 20:2921-7. 2002..089) animals, with undetectable plasma viral loads in two of the four Tat/Rev-vaccinated animals. Therefore, the results warrant further investigation of the early regulatory proteins and their potential for vaccination against HIV...
- Generation of recombinant fowlpox virus using the non-essential F11L orthologue as insertion site and a rapid transient selection strategyDenise Boulanger
GSF Institute for Molecular Virology, Trogerstr 4 b, 81675, Munich, Germany
J Virol Methods 106:141-51. 2002..Rapid isolation of those recombinants was achieved by using a double selective system and linearising the vector plasmid before transfection...
- Differences between T cell epitopes recognized after immunization and after infectionThorsten U Vogel
Wisconsin National Primate Research Center, University of Wisconsin, 1220 Capital Court, Madison, WI 53715, USA
J Immunol 169:4511-21. 2002..The repertoire of the immune response detected in the peripheral blood after immunization substantially differed from the immune response detected in the peripheral blood after infection...
- Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccinesIngo Drexler
, , , Trogerstrasse 4 b, Germany
Proc Natl Acad Sci U S A 100:217-22. 2003..Our data provide a basis to rationally estimate immunogenicity of safe, second-generation poxvirus vaccines and suggest that MVA may be a suitable candidate...
- Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 micePeter Öhlschläger
Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, D 69120 Heidelberg, Germany
J Virol 77:4635-45. 2003....
- Improved host range selection for recombinant modified vaccinia virus AnkaraCaroline Staib
GSF-National Research Center for Environment and Health, Munich, Germany
Biotechniques 34:694-6, 698, 700. 2003
- Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus releaseAndrea Meiser
GSF Institute for Molecular Virology, Trogerstrasse 4b, 81675 Munich, Germany
J Gen Virol 84:1383-92. 2003..5-fold more CEVs at the cell surface at 24 h p.i., compared with both WR and IHD-J. Accordingly, we found that despite the presence of two in-frame deletions in the A36R gene of MVA, this virus was able to make actin tails in CEFs...
- Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3LSimone Hornemann
, Munich, Germany
J Virol 77:8394-407. 2003..We conclude that efficient propagation of MVA in CEF, the tissue culture system used for production of MVA-based vaccines, essentially requires conserved E3L gene function as an inhibitor of apoptosis and/or IFN induction...
- Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trialMassimo Di Nicola
Cristina Gandini Bone Marrow Transplantation Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan I-20133, Italy
Hum Gene Ther 14:1347-60. 2003
- Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and manCarina Lotz
Department of Hematology and Oncology, Johannes Gutenberg-University, Mainz, Germany
Int J Cancer 108:571-9. 2004..Our studies have important implications for the design of anti-Tyr-based immunotherapeutics...
- Construction and isolation of recombinant MVACaroline Staib
Institute of Molecular Virology, GSF-Research Center and Technical University Munich, Munich, Germany
Methods Mol Biol 269:77-100. 2004..This chapter provides state-of-the-art protocols for generation, plaque isolation, molecular characterization, as well as amplification and purification of MVA vector viruses to obtain recombinant viruses for further evaluation...
- Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigensGerrit Koopman
Department of Virology, Biomedical Primate Research Centre, Lange Kleiweg 139, 2288 GJ Rijswijk, The Netherlands
J Gen Virol 85:2915-24. 2004..Although limited in the number of animals, this study provides important proof of the efficacy of the triple-vector vaccine strategy against chronic, progressive CD4+ T-cell loss in the rigorous SIVmac/rhesus macaque model of AIDS...
- Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteinsWieslawa Olszewska
Department of Respiratory Medicine, National Heart and Lung Institute, Faculty of Medicine, Imperial College at St Mary's, Paddington, London W2 1PG, UK
Vaccine 23:215-21. 2004..Thus, MVA vaccines induce a favourable immune profile in RSV disease but retain the potential to enhance disease...
- Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239Thorsten U Vogel
Wisconsin Primate Research Center. Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin 53715, USA
J Virol 77:13348-60. 2003....
- Role of viral factor E3L in modified vaccinia virus ankara infection of human HeLa Cells: regulation of the virus life cycle and identification of differentially expressed host genesHolger Ludwig
, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany
J Virol 79:2584-96. 2005....
- Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD95 down-regulation and defines scrapins, a new group of surface cellular receptor abductor proteinsJean Luc Guerin
, , 31076 Toulouse, France
J Virol 76:2912-23. 2002..The down-regulation of cell surface molecules by scrapins probably helps protect infected cells during viral infections...